Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
This regulatory change allowed doctors to prescribe the medication to patients without diabetes who met obesity criteria, dramatically expanding the eligible population
"One of the limitations of a real-world study is we do not know why six out of 10 people did not take the medication continuously," said Dr
In a 2023 Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al.), retatrutide produced 22.8% to 24.2% mean weight loss at 48 weeks at the higher doses (8 to 12 mg)
Women report nausea on GLP-1s at roughly 2.5 times the rate men do at the same dose, and the standard titration schedule is where most women quit
Clinical evidence is evolving, and more research is required to fully establish long-term safety and efficacy
US$ 27.71
US$ 27.03
US$ 23.84
